| Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance SY Ku, S Rosario, Y Wang, P Mu, M Seshadri, ZW Goodrich, ... Science 355 (6320), 78-83, 2017 | 916 | 2017 |
| SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer P Mu, Z Zhang, M Benelli, WR Karthaus, E Hoover, CC Chen, ... Science 355 (6320), 84-88, 2017 | 910 | 2017 |
| Towards precision oncology in advanced prostate cancer SY Ku, ME Gleave, H Beltran Nature Reviews Urology 16 (11), 645-654, 2019 | 200 | 2019 |
| Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer H Beltran, A Romanel, V Conteduca, N Casiraghi, M Sigouros, ... The Journal of clinical investigation 130 (4), 1653-1668, 2020 | 159 | 2020 |
| YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage E Ciamporcero, H Shen, S Ramakrishnan, S Yu Ku, S Chintala, L Shen, ... Oncogene 35 (12), 1541-1553, 2016 | 126 | 2016 |
| Transcriptional mediators of treatment resistance in lethal prostate cancer MX He, MS Cuoco, J Crowdis, A Bosma-Moody, Z Zhang, K Bi, A Kanodia, ... Nature medicine 27 (3), 426-433, 2021 | 116 | 2021 |
| TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup DP Labbé, CJ Sweeney, M Brown, P Galbo, S Rosario, KM Wadosky, ... Clinical Cancer Research 23 (22), 7072-7083, 2017 | 113 | 2017 |
| Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models E Ciamporcero, KM Miles, R Adelaiye, S Ramakrishnan, L Shen, SY Ku, ... Molecular cancer therapeutics 14 (1), 101-110, 2015 | 110 | 2015 |
| Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer SC Baca, DY Takeda, JH Seo, J Hwang, SY Ku, R Arafeh, T Arnoff, ... Nature Communications 12 (1), 1979, 2021 | 95 | 2021 |
| Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer L Ellis, SY Ku, S Ramakrishnan, E Lasorsa, G Azabdaftari, A Godoy, R Pili Oncotarget 4 (12), 2225, 2013 | 86 | 2013 |
| Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications R Adelaiye, E Ciamporcero, KM Miles, P Sotomayor, J Bard, M Tsompana, ... Molecular cancer therapeutics 14 (2), 513-522, 2015 | 72 | 2015 |
| Therapeutic targeting of TFE3/IRS-1/PI3K/mTOR axis in translocation renal cell carcinoma NP Damayanti, JA Budka, HWZ Khella, MW Ferris, SY Ku, E Kauffman, ... Clinical Cancer Research 24 (23), 5977-5989, 2018 | 70 | 2018 |
| Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer JS Kirk, K Schaarschuch, Z Dalimov, E Lasorsa, SY Ku, S Ramakrishnan, ... Oncotarget 6 (5), 3136, 2015 | 66 | 2015 |
| SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy V Conteduca, SY Ku, L Puca, M Slade, L Fernandez, J Hess, R Bareja, ... Molecular cancer therapeutics 19 (5), 1157-1164, 2020 | 60 | 2020 |
| HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma S Ramakrishnan, SY Ku, E Ciamporcero, KM Miles, K Attwood, S Chintala, ... BMC cancer 16, 1-15, 2016 | 55 | 2016 |
| Epigenetics in prostate cancer: clinical implications V Conteduca, J Hess, Y Yamada, SY Ku, H Beltran Translational andrology and urology 10 (7), 3104, 2021 | 40 | 2021 |
| Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer MK Bakht, Y Yamada, SY Ku, VB Venkadakrishnan, JA Korsen, ... Nature cancer 4 (5), 699-715, 2023 | 39 | 2023 |
| Activated ALK cooperates with N-Myc via Wnt/β-catenin signaling to induce neuroendocrine prostate cancer K Unno, ZR Chalmers, S Pamarthy, R Vatapalli, Y Rodriguez, B Lysy, ... Cancer research 81 (8), 2157-2170, 2021 | 34 | 2021 |
| Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis V Conteduca, SY Ku, L Fernandez, A Dago-Rodriquez, J Lee, A Jendrisak, ... NPJ precision oncology 5 (1), 76, 2021 | 30 | 2021 |
| Generation of a C57BL/6 MYC‐Driven Mouse Model and Cell Line of Prostate Cancer L Ellis, SY Ku, Q Li, G Azabdaftari, J Seliski, B Olson, CS Netherby, ... The Prostate 76 (13), 1192-1202, 2016 | 27 | 2016 |
